Could long Covid be solved by autoantibodies?
Swiss researchers have found a new class of 'good autoantibodies', which are associated with a favourable course and lower risk of long-Covid.
List view / Grid view
Swiss researchers have found a new class of 'good autoantibodies', which are associated with a favourable course and lower risk of long-Covid.
Using Agilent Seahorse XF technology with the XF Mito Tox Assay allows for streamlined, reliable identification of mitochondrial toxicants.
A selective FACS-enrichment was performed via the enrichment mode of Namocell Single Cell Dispenser to enrich for high titer CHO cells.
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
Watch Dr David Rimm from the Yale School of Medicine talk about his recent work and take on the future of multiplex spatial profiling of the TME.
The team used these models to show drug responses and established a CRISPR-screening platform to identify potential therapeutic targets for non-alcoholic fatty liver disease.
By creating a drug that is based on part of the SARS-CoV-2 spike protein, US and Finnish researchers can block the virus from entering cells.
To help people with opioid addiction, US researchers are turning to AI to create and optimise potential new drugs.
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
Oestrogen receptors play a crucial role in breast cancer. By making them therapeutic targets, oestrogen can be regulated with the aim to prevent breast cancer.
US researchers evaluate an experimental gene therapy in the first ever nonhuman primate model for Usher Syndrome.
US researchers investigate how bacteria develop an antibiotic tolerance without mutations.
Discover how the Agilent Seahorse XF Real Time ATP rate assay provides a simple robust workflow that can identify metabolic targets for drug discovery
US researchers spotlight how p53, the most frequently mutated tumour suppressor gene, can be activated against cancer cells.